Network Biomedical Research Center for Liver and Digestive Diseases (CIBEREHD)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Senior researcher at the Aragon Institute of Health Sciences, the Aragon Health Research Institute, and member of the CIBER in liver and digestive diseases (CIBERehd)
Professor of Immunology in the Department of Immunology, Ophthalmology and ENT of the Complutense University of Madrid, member of the Gregorio Marañón Health Research Institute of Madrid and the Networked Biomedical Research Center for Liver and Digestive Diseases (CIBEREHD)
Research Professor at IDIBAPS-Hospital Clínic de Barcelona and Scientific Director of CIBEREHD - Carlos III Health Institute
Research estimates that 15.6 million people born between 2008 and 2017 worldwide will develop gastric cancer at some point in their lives if current trends continue. In Spain, there would be 58,641 cases, or 1.24% of people in this age group. The team used data on gastric cancer from 185 countries in 2022 combined with mortality projections based on United Nations demographic data. The estimates, published in the journal Nature Medicine, show that 76% of cases could be attributed to Helicobacter pylori, a common bacterium found in the stomach.
Five out of ten potential treatments move from animal studies to human studies; four to randomised controlled clinical trials; and one in 20 moves on to approval by regulatory agencies, an analysis estimates. Concordance between positive results in animals and in clinical studies is 86%, according to the study, published in PLoS Biology, which pools the findings of 122 published studies on 54 different human diseases.